TEAD transcription factors emerge as a new frontier in cancer therapy

For years, cancer researchers have chased the engines that drive uncontrolled cell growth, and few engines have proven as tantalizing — or as stubborn — as the Hippo pathway. At the heart of this signaling network sit four transcription factors known as TEAD1 through TEAD4, proteins that act as molecular switches controlling which genes a cell reads and when. A comprehensive review published in Molecular Cancer now maps the full landscape of TEAD biology in cancer, from the structural details that make these proteins druggable to the clinical trials testing whether blocking them can finally help patients. The verdict is nuanced: TEAD inhibition is showing real promise, particularly in mesothelioma, but the path to durable treatments will demand smarter patient selection and a deeper understanding of when tumors truly depend on this pathway.

The TEAD family occupies a unique position in cell biology. These are transcription factors, meaning they bind DNA and regulate gene expression, yet they possess no DNA-binding capability of their own in the classical sense — instead, they rely on coactivator partners, most famously YAP1 and its close relative TAZ, to become fully functional. When the Hippo pathway is active, a kinase cascade involving MST1/2 and LATS1/2 phosphorylates YAP1 and TAZ, trapping them outside the nucleus and keeping TEAD relatively quiet. When Hippo signaling falters — through loss of the tumor suppressor NF2, also known as Merlin, or through mutations in other pathway components — YAP1 and TAZ flood into the nucleus, latch onto TEAD proteins, and unleash transcriptional programs that promote cell proliferation, survival, and tissue growth. In development, this system is essential for organs to reach their proper size; in cancer, it becomes a hijacked growth program.

What makes the new review particularly valuable is its insistence on paralog-specific biology — the idea that TEAD1, TEAD2, TEAD3, and TEAD4 are not interchangeable cogs but distinct entities with different expression patterns, cofactor preferences, and functional consequences. The four TEAD proteins share a conserved architecture, including an N-terminal TEA domain that contacts DNA and a C-terminal YAP1-binding domain that hosts the coactivator interface. Yet their roles diverge across tissues and tumor types. This matters enormously for drug development: a therapy designed to hit all four paralogs equally may produce toxicity profiles very different from one that selectively targets the paralog driving a particular cancer. The review argues that understanding which TEAD paralog matters in which context could be the key to both efficacy and tolerability.

Regulation of TEAD activity extends far beyond the canonical Hippo kinase cascade. The review catalogs an impressive array of non-canonical inputs: mechanical forces transmitted through the cytoskeleton and focal adhesion kinase, oncogenic signals from G-protein-coupled receptors, RHOA, and the MAPK and PI3K pathways, metabolic states sensed through AMPK and alanyl-tRNA synthetase 1, and even hypoxia acting through HIF-1α. A particularly important post-translational modification is palmitoylation — the attachment of a fatty acid chain to a conserved cysteine residue deep within a hydrophobic pocket of every TEAD protein. This lipid modification is essential for TEAD stability and for its interaction with YAP1 and TAZ, and it has become the single most exploited vulnerability in the drug-development field.

That vulnerability has spawned an entire class of experimental drugs known as TEAD lipid-pocket inhibitors. By occupying the palmitoylation pocket, these molecules destabilize TEAD proteins and disrupt their ability to drive transcription, effectively silencing the pathway regardless of upstream signals. The clinical star of this approach is VT3989, a lipid-pocket inhibitor that has generated genuine excitement with early results in malignant mesothelioma — a cancer notoriously resistant to standard therapies and frequently driven by loss of the NF2 tumor suppressor. Early clinical findings suggest that TEAD inhibition can produce meaningful antitumor activity in this population, offering the first direct validation in humans that the Hippo-TEAD axis is a viable therapeutic target. Yet the review is careful to flag unresolved questions: how durable are the responses, which patients benefit most, and how should renal tolerability signals be managed?

The dependence question is where the biology becomes genuinely subtle. The review draws a sharp distinction between tumors with strong, lineage-defined YAP1/TAZ-TEAD dependence — NF2-deficient mesothelioma being the paradigm case — and settings where the pathway plays a supporting role in tumor plasticity, immune evasion, and resistance to other treatments, or may even restrain tumor growth in some contexts. In other words, simply measuring TEAD expression or pathway activation in a tumor does not tell you whether that tumor will collapse when you drug the pathway. Some cancers use TEAD signaling as their primary fuel; others merely borrow it episodically to survive stress, change identity, or hide from immunotherapy. This distinction has profound implications for clinical trial design, because enrolling patients based on biomarkers that do not reflect functional dependence is a recipe for disappointing results.

Beyond lipid-pocket inhibitors, the therapeutic arsenal is diversifying rapidly. The review describes molecules that directly disrupt the protein-protein interaction between YAP1/TAZ and TEAD, proteolysis-targeting chimeras — PROTACs — that physically destroy TEAD proteins by recruiting the cellular degradation machinery, compounds that induce cofactor switching to reprogram TEAD’s transcriptional output, and YAP1-directed oligonucleotide therapeutics that silence the coactivator itself. Each modality carries distinct advantages: degraders may achieve more complete pathway suppression than inhibitors, interaction disruptors may spare TEAD functions independent of YAP1/TAZ, and oligonucleotides offer a route to targeting the pathway at the RNA level. The diversity of approaches reflects both the field’s enthusiasm and its recognition that no single strategy has yet proven sufficient.

Resistance, predictably, is already emerging as a central challenge. The review documents multiple mechanisms by which tumors can escape TEAD-targeted therapy, and it emphasizes that rational combination strategies — pairing TEAD inhibitors with agents matched to specific escape routes — will be essential. Equally important is the development of pharmacodynamic biomarkers that confirm the drug is actually engaging its target in the tumor, such as measuring the suppression of canonical TEAD target genes like CTGF and CYR61. Without such confirmation, clinicians cannot distinguish true drug resistance from inadequate target engagement, and trial results become difficult to interpret.

The review also situates TEAD biology within the broader tumor microenvironment. YAP1/TAZ-TEAD signaling in cancer-associated fibroblasts shapes the extracellular matrix and secretes inflammatory cytokines including interleukin-6 and interleukin-8, while in immune cells it can influence programs of immune suppression. This means TEAD inhibition may not only kill tumor cells directly but also remodel the tumor’s surroundings in ways that could synergize with immunotherapy — a hypothesis the review presents as an area of active investigation rather than settled fact. The interplay between mechanical cues, stromal signaling, and TEAD activity underscores why this pathway cannot be understood in isolation from the tissue context in which tumors arise.

Ultimately, the review’s message is one of disciplined optimism. The TEAD transcription factors have moved from basic biology to the clinic in a remarkably short time, and the early mesothelioma data with VT3989 prove the concept is sound. But the authors are clear-eyed about what comes next: the field needs functional biomarkers of TEAD dependence rather than crude measures of pathway activation, rigorous pharmacodynamic monitoring in every trial, and combination regimens built on mechanistically defined resistance pathways rather than guesswork. Progress, they conclude, will depend on translating the mechanistic insights accumulated over two decades of Hippo pathway research into durable antitumor efficacy at tolerable exposures, in the patients most likely to benefit. For a pathway once considered undruggable, that is a goal now firmly within reach — provided the science of patient selection catches up with the science of the target.

Subject of Research: TEAD transcription factors in the Hippo pathway as therapeutic targets in cancer

Article Title: Targeting TEAD in cancers: paralog-specific biology, resistance and therapeutic opportunities

Article References: Targeting TEAD in cancers: paralog-specific biology, resistance and therapeutic opportunities. (n.d.). https://doi.org/10.1186/s12943-026-02809-0

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02809-0

Keywords: TEAD, Hippo pathway, YAP1, TAZ, NF2, mesothelioma, transcription factors, cancer therapy, lipid-pocket inhibitors, drug resistance, biomarkers, VT3989